Monday, November 13, 2006 7:00:00 AM PDT | VentureDeal Staff
ANN ARBOR, MI -- Cerenis Therapeutics, an Ann Arbor-based pharmaceutical company developing treatments for cardiovascular and metabolic diseases, announced the closing of a $53.5 million Series B round of financing. The round was led by TVM Capital and included OrbiMed and previous investors Sofinnova Partners, Healthcap of Sweden, Alta Partners, EDF Ventures and NIF SMBC Ventures of Japan. Funding proceeds will go towards continued development of the company's offerings in treating atherosclerosis.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
